ANGLE PLC Announces Result of 2025 Annual General Meeting
ANGLE plc (OTCQX:ANPCY), a world-leading liquid biopsy company, has announced that all resolutions presented at its 2025 Annual General Meeting were successfully passed. The company will make detailed voting results available on its corporate website.
ANGLE plc (OTCQX:ANPCY), azienda leader mondiale nel settore delle biopsie liquide, ha annunciato che tutte le delibere presentate durante l'Assemblea Generale Annuale del 2025 sono state approvate con successo. L'azienda renderà disponibili i risultati dettagliati delle votazioni sul proprio sito web aziendale.
ANGLE plc (OTCQX:ANPCY), una empresa líder mundial en biopsias líquidas, ha anunciado que todas las resoluciones presentadas en su Asamblea General Anual de 2025 fueron aprobadas con éxito. La compañía pondrá a disposición los resultados detallados de las votaciones en su sitio web corporativo.
ANGLE plc (OTCQX:ANPCY)는 세계적인 액체 생검 선도 기업으로서 2025년 연례 주주총회에서 제시된 모든 안건이 성공적으로 통과되었음을 발표했습니다. 회사는 투표 결과 상세 내역을 자사 웹사이트에 공개할 예정입니다.
ANGLE plc (OTCQX:ANPCY), une entreprise mondiale de premier plan dans le domaine de la biopsie liquide, a annoncé que toutes les résolutions présentées lors de son Assemblée Générale Annuelle 2025 ont été adoptées avec succès. La société mettra à disposition les résultats détaillés des votes sur son site internet corporate.
ANGLE plc (OTCQX:ANPCY), ein weltweit führendes Unternehmen im Bereich der Flüssigbiopsie, hat bekannt gegeben, dass alle auf der Hauptversammlung 2025 vorgestellten Beschlüsse erfolgreich angenommen wurden. Das Unternehmen wird die detaillierten Abstimmungsergebnisse auf seiner Unternehmenswebsite veröffentlichen.
- None.
- None.
Result of 2025 Annual General Meeting
GUILDFORD, SURREY / ACCESS Newswire / June 30, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.
Details of the voting will be available on the Company's website in due course.
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director | |
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser | +44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) | +44 (0) 203 727 1000 +1 (212) 850 5624 |
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
When was ANGLE plc's (ANPCY) 2025 Annual General Meeting held?
What was the outcome of ANGLE plc's (ANPCY) 2025 Annual General Meeting?
Where can shareholders find the voting details from ANGLE plc's 2025 AGM?
Who is the Chief Executive of ANGLE plc (ANPCY)?
